Investors Buy High Volume of Rockwell Medical Put Options (RMTI)
Rockwell Medical Inc (NASDAQ:RMTI) was the recipient of some unusual options trading on Thursday. Stock investors bought 3,054 put options on the stock. This is an increase of 3,815% compared to the average daily volume of 78 put options.
Rockwell Medical (RMTI) opened at $5.92 on Friday. The company has a market capitalization of $318.25, a P/E ratio of -13.77 and a beta of 2.02. Rockwell Medical has a 52-week low of $5.06 and a 52-week high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $14.63 million for the quarter, compared to analyst estimates of $13.33 million. Rockwell Medical had a negative return on equity of 47.93% and a negative net margin of 34.57%. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.09) earnings per share. equities research analysts anticipate that Rockwell Medical will post -0.44 EPS for the current fiscal year.
Several research analysts recently commented on the company. BidaskClub cut Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research cut Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th.
ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2018/01/20/investors-buy-high-volume-of-rockwell-medical-put-options-rmti.html.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.